Clinical trials: Other Connective Tissue Diseases
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Still's Disease, Adult-Onset, Sepsis
Glycosylated Ferritin in Macrophagic Activation Syndromes
In healthy subjects, from 50 to 80 % of the serum ferritin is glycosylated [1, 2] . A decrease in the percentage of ferritin glycosylation can be observed in inflammatory diseases, malignancies, infections, or liver disease but…
- Conditions
- Still's Disease, Adult-Onset, Sepsis, Macrophagic Activation Syndrome
- Trial name
- FERRITGLY01 (NCT02143986)
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Brugmann University Hospital
Mucopolysaccharidosis II
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.
- Trial name
- NCT00069641
- Testing
- Iduronate-2-sulfatase enzyme replacement therapy
- Where
- 9 sites in United States, Brazil and 2 more
- Volunteers
- 96 people
- Sponsor
- Shire
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Atopic Dermatitis, Skin Diseases
Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
This study aims at evaluating the effect of a topical product on the improvement of quality of life and pain of patients suffering from atopic dermatitis or other skin diseases with dryness or severe xerosis.
- Trial name
- NCT05765461
- Where
- 7 sites in Croatia, Germany and 5 more
- Volunteers
- 4,631 people
- Sponsor
- Cosmetique Active International
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Autonomic Failure, Dysautonomia
Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies
People with POTS, autoimmune autonomic neuropathy (AAN), pure autonomic failure (PAF), SFN and Ehlers Danlos Syndrome (EDS) do not only suffer from orthostatic symptoms such as dizziness, headache, neck pain, blurred vision or…
- Conditions
- Autonomic Failure, Dysautonomia, Cognitive Impairment, Ehlers-Danlos Syndrome
- Trial name
- POTSKog (NCT03681080)
- Testing
- leg crossing
- Where
- Germany
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Advanced Solid Tumor
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated…
- Trial name
- NCT04890613
- Testing
- CX-5461
- Where
- 8 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Senhwa Biosciences, Inc.
Breast Cancer
Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions
RATIONALE: A questionnaire that evaluates a patient's expectations about breast reconstruction surgery may help doctors improve patient education before surgery and increase patient satisfaction after surgery.
- Trial name
- NCT00471601
- Testing
- counseling intervention, questionnaire administration, psychosocial assessment and care
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 357 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Degenerative Osteoarthritis, Rheumatoid Arthritis
All Polyethylene Tibia-VEGA Kiel
Obligatory Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation For this PMCF only CE-marked medical devices will be used within their intended purpose and…
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Post-traumatic; Arthrosis, Other Instability, Knee
- Trial name
- APT-VEGA_KI (NCT02756702)
- Testing
- All-Poly
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Aesculap AG
Breast Cancer
PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors
The improvement of the healing rates for breast cancer is based to an important part on the consistent use of so-called adjuvant ("supporting ") medicamentous therapies, including chemotherapy.
- Trial name
- PiA (NCT01592825)
- Volunteers
- 1,000 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Skin Rash
Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).
- Trial name
- NCT00709878
- Testing
- Skin Biopsy of Skin Rash Secondary to EGFRI Use
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Breast Cancer
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT)…
- Trial name
- NCT05339685
- Testing
- BL-M02D1
- Where
- 10 sites in China
- Volunteers
- 82 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Psoriasis
Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database
The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.
- Trial name
- NCT01081730
- Testing
- anti-TNF biologics, general population, non-anti-TNF biologics
- Volunteers
- 2,040 people
- Sponsor
- Janssen Biotech, Inc.
Breast Cancer, Gestational Trophoblastic Tumor
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side…
- Conditions
- Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma
- Trial name
- NCT00004157
- Testing
- filgrastim, recombinant interleukin-11
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- NCT06120283
- Testing
- BGB-43395, Fulvestrant, Letrozole
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 433 people
- Sponsor
- BeOne Medicines
Degenerative Disease, Oncology
Comprehensive Segmental Revision System
Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System.
- Conditions
- Degenerative Disease, Oncology, Revision Surgery, Trauma
- Trial name
- NCT03270982
- Testing
- Comprehensive SRS Replacement
- Where
- 4 sites in Canada, Denmark and 1 more
- Volunteers
- 105 people
- Sponsor
- Zimmer Biomet
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Malignant Mesothelioma, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Malignant Mesothelioma, Pancreatic Cancer, Ovarian Tumor, Triple Negative Breast Cancer
- Trial name
- NCT02580747
- Testing
- anti-meso-CAR vector transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital